Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > generic: None

& classes: D2/D3/5HT1A partial agonist

& fda max: 6 mg/d (psychosis/mania); 3 mg/d (depression adjunct)

Use the filters below to narrow your results.

Vraylar (1)

None (1)

Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1)

Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1)

1.5 mg, 3 mg, 4.5 mg, 6 mg capsules (1)

Oral (1)

Weeks for psychosis/mood efficacy (1)

Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks) (1)

Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses (1)

Adequate oral bioavailability (1)

Limited data (1)

Rx (1)

Showing below up to 1 result in range #1 to #1.

C

Cariprazine

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"